S&P 500   2,993.19 (-0.16%)
DOW   26,847.23 (-0.66%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
FB   185.92 (-2.35%)
MSFT   138.05 (-1.17%)
GOOGL   1,245.66 (-0.57%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
MU   43.47 (-4.46%)
GE   8.99 (-0.55%)
TSLA   256.90 (-1.94%)
T   38.23 (+1.08%)
F   9.29 (+1.98%)
ACB   3.71 (-4.63%)
PRI   124.22 (+0.12%)
NFLX   276.40 (-5.78%)
BAC   30.45 (+0.63%)
GILD   64.23 (-1.53%)
DIS   131.27 (-0.83%)
S&P 500   2,993.19 (-0.16%)
DOW   26,847.23 (-0.66%)
QQQ   192.03 (-0.79%)
AAPL   236.13 (+0.36%)
FB   185.92 (-2.35%)
MSFT   138.05 (-1.17%)
GOOGL   1,245.66 (-0.57%)
AMZN   1,763.32 (-1.35%)
CGC   20.00 (-3.66%)
MU   43.47 (-4.46%)
GE   8.99 (-0.55%)
TSLA   256.90 (-1.94%)
T   38.23 (+1.08%)
F   9.29 (+1.98%)
ACB   3.71 (-4.63%)
PRI   124.22 (+0.12%)
NFLX   276.40 (-5.78%)
BAC   30.45 (+0.63%)
GILD   64.23 (-1.53%)
DIS   131.27 (-0.83%)
Log in

AbbVie Stock Price, News & Analysis (NYSE:ABBV)

$76.88
+1.74 (+2.32 %)
(As of 10/18/2019 03:29 PM ET)
Today's Range
$75.21
Now: $76.88
$77.00
50-Day Range
$65.30
MA: $71.38
$76.25
52-Week Range
$62.66
Now: $76.88
$94.98
Volume5.27 million shs
Average Volume7.51 million shs
Market Capitalization$113.67 billion
P/E Ratio9.72
Dividend Yield5.74%
Beta0.99
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$32.75 billion
Cash Flow$9.63 per share
Book Value($5.61) per share

Profitability

Net Income$5.69 billion

Miscellaneous

Employees30,000
Outstanding Shares1,478,480,000
Market Cap$113.67 billion
Next Earnings Date11/1/2019 (Confirmed)
OptionableOptionable

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.


AbbVie (NYSE:ABBV) Frequently Asked Questions

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a -- dividend on Monday, September 9th. Investors of record on Tuesday, October 15th will be paid a dividend of $1.07 per share on Friday, November 15th. This represents a yield of 6.4%. The ex-dividend date of this dividend is Friday, October 11th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie declared that its Board of Directors has authorized a stock buyback plan on Thursday, December 13th 2018, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 3.8% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's leadership believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc (NYSE:ABBV) announced its quarterly earnings results on Friday, July, 26th. The company reported $2.26 EPS for the quarter, topping the Zacks' consensus estimate of $2.21 by $0.05. The business earned $8.26 billion during the quarter, compared to the consensus estimate of $8.09 billion. AbbVie had a negative return on equity of 182.70% and a net margin of 12.62%. AbbVie's revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.00 EPS. View AbbVie's Earnings History.

When is AbbVie's next earnings date?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, November 1st 2019. View Earnings Estimates for AbbVie.

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Friday, November 1st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY19 earnings guidance on Friday, July, 26th. The company provided earnings per share (EPS) guidance of $8.82-8.92 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.78.

What price target have analysts set for ABBV?

15 equities research analysts have issued twelve-month price targets for AbbVie's shares. Their predictions range from $66.61 to $135.00. On average, they expect AbbVie's stock price to reach $89.20 in the next twelve months. This suggests a possible upside of 16.0% from the stock's current price. View Analyst Price Targets for AbbVie.

What is the consensus analysts' recommendation for AbbVie?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Has AbbVie been receiving favorable news coverage?

Media headlines about ABBV stock have trended neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AbbVie earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for AbbVie.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 65)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 53)
  • Mr. Robert A. Michael, Sr. VP & CFO (Age 49)
  • Mr. William J. Chase, Exec. VP of Fin. & Admin. (Age 51)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 56)

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Robeco Institutional Asset Management B.V. (0.20%), Envestnet Asset Management Inc. (0.09%), PGGM Investments (0.08%), Hamlin Capital Management LLC (0.07%), Artemis Investment Management LLP (0.06%) and Miller Howard Investments Inc. NY (0.05%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Park National Corp OH, Bowling Portfolio Management LLC, Security National Bank, Gateway Investment Advisers LLC, Decatur Capital Management Inc., Nisa Investment Advisors LLC and Global Trust Asset Management LLC. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Richard A Gonzalez, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Which institutional investors are buying AbbVie stock?

ABBV stock was purchased by a variety of institutional investors in the last quarter, including PGGM Investments, Miller Howard Investments Inc. NY, Robeco Institutional Asset Management B.V., Commerzbank Aktiengesellschaft FI, TIAA FSB, Rhenman & Partners Asset Management AB, Hamlin Capital Management LLC and Envestnet Asset Management Inc.. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin and William J Chase. View Insider Buying and Selling for AbbVie.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $76.88.

How big of a company is AbbVie?

AbbVie has a market capitalization of $113.67 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.View Additional Information About AbbVie.

What is AbbVie's official website?

The official website for AbbVie is http://www.abbvie.com/.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (NYSE ABBV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  978 (Vote Outperform)
Underperform Votes:  661 (Vote Underperform)
Total Votes:  1,639
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe ABBV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABBV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel